Independent Market Research Read Our Recent Desk Notes Alcidion Group Ltd (ASX: ALC) – Making Healthcare Flow11 Nov 2026Clever Culture Systems Ltd (ASX: CC5) – Culturing Bigger Ambitions4 Nov 2026EMVision Medical Devices Ltd (ASX: EMV) – A Stroke of Innovation: Brain Imaging Beyond the Hospital29 Oct 2026OncoSil Medical (ASX: OSL) – US Reimbursement Decision Anchors Near-Term Catalysts26 Oct 2026Cogstate Ltd (ASX: CGS) – Building a Global Leader in Cognitive Assessments14 Oct 2026Island Pharmaceuticals (ASX: ILA) – The Path to Approval Without a Human Efficacy Trial8 Oct 2026Entropy Neurodynamics Limited (ASX: ENP) – Sector Momentum Builds Ahead of ENP’s Next Clinical Readouts30 Sep 2026Neurotech International Ltd (ASX: NTI) – First Patient Dosed, Pivotal Study Begins23 Sep 2026Arovella Therapeutics (ASX: ALA) – Arovella Nears First Patient Dosing with ALA-10115 Sep 2026Optiscan Imaging Limited (ASX: OIL) – Optiscan Builds Toward Dual FDA Submissions8 Sep 2026Actinogen Medical Ltd (ASX: ACW) – Xanamem Approaches a Defining Readout2 Sep 2026Paradigm Biopharmaceuticals (ASX: PAR) – Zilosul Approaches Its First Phase 3 Read Out25 Aug 2026OncoSil Medical (OSL) – Breaks Into the US18 Aug 2026Entropy (ENP) – 72 Patients, Nine Cohorts, Eight Disorders: Entropy Broadens the Platform4 Aug 2026CTS – Newly Listed Alzheimer’s Medical Device Targets US$18 billion Market, Debuts +132%28 Jul 2026SNT – 1st Cohort of AZALOX Trial Complete, Preliminary Data Expected Q4 CY2621 Jul 2026OSL – Delivers on Milestones as Stock Re-Rates, Catalysts Still Ahead14 Jul 2026ENP – Entropy Reports Cohort 1 Topline Results in Treatment-Resistant Binge Eating Disorder10 Jul 2026ILA – Galidesivir Cleared for Compassionate Use in the Bundibugyo Ebola Outbreak7 Jul 2026OSL – Regulatory Progress Supports a Catalyst-Rich 2H CY20263 Jul 2026
